FR2942409B1 - PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION. - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION.

Info

Publication number
FR2942409B1
FR2942409B1 FR0951105A FR0951105A FR2942409B1 FR 2942409 B1 FR2942409 B1 FR 2942409B1 FR 0951105 A FR0951105 A FR 0951105A FR 0951105 A FR0951105 A FR 0951105A FR 2942409 B1 FR2942409 B1 FR 2942409B1
Authority
FR
France
Prior art keywords
abortion
repetitive
prevention
pharmaceutical composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0951105A
Other languages
French (fr)
Other versions
FR2942409A1 (en
Inventor
Natacha Voillot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR0951105A priority Critical patent/FR2942409B1/en
Publication of FR2942409A1 publication Critical patent/FR2942409A1/en
Application granted granted Critical
Publication of FR2942409B1 publication Critical patent/FR2942409B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0951105A 2009-02-20 2009-02-20 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION. Expired - Fee Related FR2942409B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0951105A FR2942409B1 (en) 2009-02-20 2009-02-20 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0951105A FR2942409B1 (en) 2009-02-20 2009-02-20 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION.

Publications (2)

Publication Number Publication Date
FR2942409A1 FR2942409A1 (en) 2010-08-27
FR2942409B1 true FR2942409B1 (en) 2013-07-26

Family

ID=41129226

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0951105A Expired - Fee Related FR2942409B1 (en) 2009-02-20 2009-02-20 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION.

Country Status (1)

Country Link
FR (1) FR2942409B1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761992B1 (en) * 1997-04-09 1999-06-11 Hoechst Marion Roussel Inc NOVEL 4-HALOGEN STEROIDS, THEIR PREPARATION PROCESS AND INTERMEDIATES, THEIR APPLICATION AS DRUGS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2778337B1 (en) * 1998-05-05 2001-08-31 Inst Nat Sante Rech Med ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS
EP1377604B1 (en) * 2001-04-12 2014-12-31 Academisch Ziekenhuis Leiden Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
WO2004006959A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
FR2849380A1 (en) * 2002-12-27 2004-07-02 Ernest Loumaye Treating sterility in female mammals, especially women, by administration of gonadotrophin-releasing hormone agonist in composition adapted for supporting the luteal phase
KR20080077024A (en) * 2005-12-19 2008-08-20 트러스티즈 오브 터프츠 칼리지 Soft protease inhibitors and pro-soft forms thereof
US20090247493A1 (en) * 2006-01-27 2009-10-01 Duramed Pharmaceuticals, Inc. Regimens for Treatment of Conditions Related to Estrogen Deficiency
KR20080091838A (en) * 2006-02-02 2008-10-14 리나트 뉴로사이언스 코퍼레이션 Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist

Also Published As

Publication number Publication date
FR2942409A1 (en) 2010-08-27

Similar Documents

Publication Publication Date Title
AP2011005979A0 (en) Pharmaceutical composition for a hepatitis C viralprotease inhibitor.
BRPI1011815A2 (en) "pharmaceutical composition for emergency contraception"
MA30236B1 (en) NEW PHARMACEUTICAL COMPOSITION
FR2959935B1 (en) ALCOHOL-RESISTANT ORAL PHARMACEUTICAL FORM
DK2442790T3 (en) AURAL PHARMACEUTICAL COMPOSITIONS, CONTAINING BORATE-POLYOL COMPLEXES
BRPI1016190A2 (en) pharmaceutical compounds.
FR2948568B1 (en) PHARMACEUTICAL FORMULATION
DK2493312T3 (en) PHARMACEUTICAL SOLID COMPOSITIONS CONTAINING AN INTEGRASE INHIBITOR
CL2007001919A1 (en) COMPOUNDS DERIVED FROM 18-METIL-15B, 16B-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS, USEFUL AS CONTRACEPTIVE.
AP2920A (en) Anti-malarial pharmaceutical composition
AP2010005343A0 (en) New dihydroindolone compounds, a process for theirpreparation and pharmaceutical compositions conta ining them.
BRPI1014214A2 (en) "aerosol dispenser."
IT1393452B1 (en) SAFETY DEVICE FOR EMERGENCY INTERRUPTION OF THE PUNCHING MANEUVER.
FR2942640B1 (en) POST-COMBUSTION CHAMBER FOR TURBOMACHINE
IL212603A (en) Combination comprising a thioester and at least one esterase inhibitor, a process for increasing the bioavailability of the thioester by such combination, a pharmaceutical composition comprising said combination and kit comprising it
FR2945952B1 (en) ANTI-CK8 ANTIBODIES FOR USE AS A MEDICINAL PRODUCT.
FR2942409B1 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF REPETITIVE ABORTION.
BRPI0811431A2 (en) Aqueous pharmaceutical composition.
FR2926722B1 (en) APPROPRIATE PHARMACEUTICAL FORMULATION FOR THE PREPARATION OF ORODISPERSIBLE PRELOISOLONE TABLETS
FR2951945B1 (en) PHARMACEUTICAL COMPOSITION
IL214136A0 (en) Chronotherapeutic pharmaceutical composition
BRPI1009131A2 (en) pharmaceutical composition comprising aliskiren
FR2916354B1 (en) PHARMACEUTICAL COMPOSITION FOR INHIBITING VASCULAR CALCIFICATION.
FR2926724B1 (en) NEW ORAL PHARMACEUTICAL FORM.
TN2011000046A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

ST Notification of lapse

Effective date: 20231005